## **ANCA and GBM Antibodies**

Accreditation Status:	UKAS Schedule of Accreditation
Date Scheme started:	1987
Clinical Applicability:	Diagnosis of autoimmune disease
Analytes:	Identification of the Neutrophil Cytoplasmic Antibodies, C-ANCA, P-ANCA, and Glomerular Basement Membrane (GBM). Quantitative assessment is currently restricted to the Proteinase 3 (PR3) and Myeloperoxidase (MPO) antibodies and to GBM antibodies, but will be extended to include other ANCA specificities as required <b>(SER/017)</b>
Units for Reporting:	Qualitative responses for the ANCA specificities; quantitative assessment of the specific antibodies in U/mL and IU/mL
Samples Distributed:	Liquid format. Normal and pathological human serum
Number of Distributions per year:	6
Number of Samples per Distribution:	2
Frequency of Distributions:	Every two months as outlined in the <b>Distribution Schedule</b>
Schedule of Analysis:	<b>Data entry</b> is via the web for the submission of results. Data analysis is commenced 21 days after sample dispatch. Late returns are accepted and will contribute to the laboratory's cumulative performance statistics
Data Analysis:	Qualitative responses for ANCA (C-ANCA and P-ANCA), MPO, PR3 and GBM are assessed in relation to the Designated Response
Performance Scoring:	MI scoring
Criteria of Performance:	Laboratory performance for ANCA is assessed over a running analytical window of 6 Distributions (12 months). The categories of performance are:    Total MIS   Good Zero   Adequate 1-2   Poor >2
Persistent Poor Performance:	Defined as being in the Poor Performance category for two or more successive Distributions